Ken Griffin Lava Therapeutics Nv Call Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Call Options
2 transactions
Others Institutions Holding LVTX
# of Institutions
26Shares Held
3.8MCall Options Held
85.8KPut Options Held
36.8K-
Redmile Group, LLC San Francisco, CA2.07MShares$3.63 Million0.24% of portfolio
-
Bruce & Co., Inc. Chicago, IL772KShares$1.35 Million0.68% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3368KShares$643,2680.1% of portfolio
-
Two Sigma Investments, LP New York, NY112KShares$196,7680.0% of portfolio
-
Pathway Financial Advisors LLC103KShares$179,3750.04% of portfolio
About LAVA Therapeutics NV
- Ticker LVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,797,700
- Market Cap $45.1M
- Description
- LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer...